↑ 薬物リストへ　← 戻る

Dpa    (DrugBank: -)

4 diseases
告示番号疾患名（ページ内リンク）臨床試験数
2筋萎縮性側索硬化症1
6パーキンソン病3
13多発性硬化症／視神経脊髄炎5
85特発性間質性肺炎1

2. 筋萎縮性側索硬化症　［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02405403
(ClinicalTrials.gov)		March 20152/3/2015Microglial Activation Role In ALS (MARIA)Microglial Activation Role In ALS (MARIA)Amyotrophic Lateral SclerosisDrug: [18F]DPA-714 PETUniversity Hospital, ToursNULLWithdrawn18 YearsN/AAll0Early Phase 1France

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03230526
(ClinicalTrials.gov)		April 20, 201818/7/2017Identification of a Biomarker Predictive of Evolution of Parkinson DiseaseBrain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?Parkinson DiseaseDrug: [18F]DPA-714 PET scanNantes University HospitalNULLRecruiting40 Years67 YearsAll64Phase 2France
2NCT03457493
(ClinicalTrials.gov)		March 22, 201823/2/2018TSPO-PET for Neuroinflammation in Parkinson's DiseaseUAB Neuroinflammation in Parkinson's Disease - TSPO-PET SubstudyParkinson DiseaseDrug: DPA-714-PET/MRIUniversity of Alabama at BirminghamNULLRecruiting30 YearsN/AAll20Phase 1;Phase 2United States
3NCT02319382
(ClinicalTrials.gov)		June 201218/11/2014Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PETHigh Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714Parkinson's Disease With LRRK2 Mutation;Healthy Controls;Parkinson's Disease Without LRRK2 MutationRadiation: PET with the tracer 18F-DPA-714;Radiation: PET with the tracer 11C-PE2I;Other: MRIAssistance Publique - Hôpitaux de ParisFrance Parkinson AssociationRecruiting18 YearsN/ABoth46N/AFrance

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03759522
(ClinicalTrials.gov)		February 3, 20196/11/2018Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;HealthyDrug: DPA-714 PET/MRIUniversity of Alabama at BirminghamNULLRecruiting18 Years65 YearsAll120Phase 1United States
2NCT03691077
(ClinicalTrials.gov)		November 11, 201828/9/2018Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714Multiple Sclerosis;Relapse;Primary Progressive Multiple SclerosisDrug: OcrelizumabAssistance Publique - Hôpitaux de ParisRoche Pharma AG;Institut du Cerveau et de la Moelle épinièreRecruiting18 Years60 YearsAll51Phase 3France
3EUCTR2017-004158-40-FR
(EUCTR)		11/09/201804/07/2018NAA Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS Patients with Relapsing MS or primary progressive MS
MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		71Phase 3France
4EUCTR2014-002547-17-NL
(EUCTR)		18/12/201401/12/2014Imaging of inflammation in the cortex of the brain in progressive MS patientsGrey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS Progressive multiple sclerosis, both primary and secondary progressive
MedDRA version: 17.1;Level: PT;Classification code 10063401;Term: Primary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 17.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: [18F]DPA-714
INN or Proposed INN: [18F]DPA-714
Other descriptive name: [18F]DPA-714		VU University Medical CenterNULLNot RecruitingFemale: yes
Male: yes		Netherlands
5NCT02305264
(ClinicalTrials.gov)		February 201225/1/2013Imaging of Intracerebral Inflammation in MSImaging of Intracerebral Inflammation in the Progressive Phase of Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary ProgressiveDrug: 18F-DPA-714 and 18F-FDGAssistance Publique - Hôpitaux de ParisNULLRecruiting18 Years65 YearsAll65N/AFrance

先頭へ


85. 特発性間質性肺炎　［臨床試験数：514，薬物数：377（DrugBank：108），標的遺伝子数：97，標的パスウェイ数：204］
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04362644
(ClinicalTrials.gov)		December 1, 20202/3/2020Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisMolecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714University of Alabama at BirminghamNULLNot yet recruiting40 Years85 YearsAll10Phase 1United States

先頭へ